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Abstract
 We performed a randomized, double-blind, placebo-controlled,
multicenter, parallel-group, dose-response study of the efficacy
and safety of the oral administration of PG-116800, a matrix
metalloproteinase (MMP) inhibitor, in patients with mild to
moderate knee osteoarthritis. The primary efficacy endpoints
included the progression of joint space narrowing in the
osteoarthritic knee, as measured by microfocal radiography with
fluoroscopic positioning, and the reduction of symptoms (pain
and stiffness) and/or the improvement of function, as measured
by the Western Ontario and McMaster Universities
osteoarthritis index (WOMAC). Four hundred and one patients
were randomly assigned to either placebo (n = 80) or one of
fourdoses of PG-116800: 25 mg (n = 81), 50 mg (n = 80), 100
mg (n = 80), or 200 mg (n = 80) taken twice daily for 12 months.
During the study, the 200-mg dose was discontinued based on
an increased frequency of musculoskeletal adverse effects.
After 1 year of treatment, no statistically significant difference
was observed between placebo and PG-116800 with regard to
mean changes in minimum joint space width of the knee or to
WOMAC scores. The most frequent adverse effect was
arthralgia (35%). Twenty-three percent of evaluable patients
had at least a 30% decrease from baseline of at least onerange-
of-motion measurement of either shoulder at a follow-up visit.
The percentage of patients with reduction in range of motion
was significantly greater in the twohighest dose groups relative
to placebo. Thirteen percent of patients, half of whom were in
the 200-mg group, reported hand adverse events (oedema,
palmar fibrosis, Dupuytren contracture, or persistent tendon
thickness or nodules). The threemost frequent shoulder adverse
events were reversible arthralgia, stiffness, and myalgia, which
mostly affected the twohighest dose groups. The unfavorable
risk-benefit balance of the MMP inhibitor PG-116800 in patients
with knee osteoarthritis precludes further development of the
compound for this indication. This study adds to the weight of
evidence suggesting that side effect profiles of MMP inhibitors
in general make them unsuitable for use in osteoarthritis.
Trial Registration ClinicalTrials.gov NCT00041756.
Introduction
Osteoarthritis (OA) is a chronic, progressive disorder of the
synovial joints, characterized by focal loss of cartilage and
changes in subchondral and marginal bone, synovium, and
periarticular structures [1]. The disorder commonly affects
weight-bearing joints and results in pain and loss of function
[2]. Current therapies (analgesics and nonsteroidal anti-inflam-
matory drugs [NSAIDs]) are mostly symptomatic and include
IDMC = Independent Data Monitoring Committee; ITT = intent-to-treat; IVRS = Interactive Voice Response System; JSW = joint space width; Med-
DRA = Medical Dictionary for Regulatory Activities; MMP = matrix metalloproteinase; MSS = musculoskeletal syndrome; NF = National Formulary; 
NSAID = nonsteroidal anti-inflammatory drug; OA = osteoarthritis; ROM = range of motion; SERM = selective estrogen-receptor modulator; 
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adjuvant interventions such as weight loss and physical ther-
apy to improve physical function. As the understanding of the
pathogenesis of joint destruction in OA increases, new thera-
peutic approaches are targeting the tissue degradation
process.
Matrix metalloproteinases (MMPs) are a group of approxi-
mately 30 proteolytic enzymes, which collectively degrade all
the components of the extracellular matrix during tissue forma-
tion and remodelling [3,4]. As degradation of the extracellular
matrix is essential for growth and progression of malignant
tumors, MMP inhibitors have been extensively studied as
potential anticancer agents [4]. MMPs have also long been
implicated in the joint destruction process that occurs in arthri-
tis, and MMP inhibitors have been studied in the treatment of
both rheumatoid arthritis and OA [5-7]. Increased levels of
MMP-1 and MMP-3 have been observed in the cartilage and
synovium of patients with OA and have been correlated with
the severity of the condition [8]. Animal models have shown
that MMPs were good therapeutic targets [9]. Despite prom-
ising preclinical data [10-13], however, development of MMP
inhibitors in arthritis seldom continued into humans, hampered
by safety issues or an unfavorable efficacy profile in other indi-
cations [14]. To our knowledge, no controlled long-term stud-
ies with MMP inhibitors in OA have been performed to date.
In long-term trials in oncology, the use of MMP inhibitors has
been associated with musculoskeletal toxicity, which was the
primary reason for program termination for some compounds
of this class [15,16]. Signs and symptoms described in the lit-
erature generally consisted of musculoskeletal pain and
inflammation, usually originating in the upper shoulder girdle or
hands, and also arthralgia, myalgia, joint stiffness, limb pain,
Dupuytren contracture, and/or peripheral pain and oedema
[4,17-23]. In published studies, musculoskeletal symptoms
tended to occur after 2 to 3 months of treatment, to be dose-
dependent, and to be generally reversible within 1 to 3 weeks
of treatment discontinuation [4,17-19,23].
PG-116800 is a member of the hydroxyproline-based
hydroxamic acid class of MMP inhibitors which has been
shown to inhibit the joint damage caused by iodoacetate injec-
tion into rat knees, an experimental model for OA [24]. PG-
116800 has high affinity for MMP-2, -3, -8, -9, -13, and -14,
the therapeutic targets, while having substantially lower affinity
for MMP-1 and -7, both of which were thought to be impli-
cated in the pathogenesis of musculoskeletal toxicity [25].
This randomized, double-blind, placebo-controlled, multi-
center, parallel-group, dose-response study was conducted to
evaluate the relative efficacy of PG-116800 versus placebo in
slowing the progression of joint space narrowing in knee OA
(structural objective) and in reducing symptoms and/or
improving function (symptomatic objective) over the course of
12 months and to assess the safety of its administration. The
minimum joint space width (JSW) in the medial compartment
of the tibiofemoral joint was measured from microfocal knee
radiographs obtained by fluoroscopic positioning. Microfocal
radiography was chosen for this study since investigators had
shown that quantitative evaluation of measurements obtained
from macroradiographs detected JSW changes within a
shorter time frame than was possible using standard radiogra-
phy [26,27]. Here, we report one of the largest studies of
MMP inhibitors and describe the adverse musculoskeletal
effects of the drug.
Materials and methods
Design and patients
Men and postmenopausal and/or hysterectomized women, 40
to 80 years of age, with primary OA of the knee according to
the American College of Rheumatology criteria [28] were eli-
gible to participate in the study. For the purpose of the radio-
graphic assessment, patients had to have at least one knee
that could be designated a 'signal knee' on microfocal x-ray, as
defined by at least oneosteophyte in either the medial or the
lateral compartment of the tibiofemoral joint (tibial spine oste-
ophytes could be included), a JSW in the medial tibiofemoral
compartment greater than or equal to 2 mm and less than 4.5
mm in the semiflexed view, and a medial compartment JSW
that was narrower than the lateral compartment JSW for the
same knee. Exclusion criteria included secondary OA, nonos-
teoarthritic causes of knee pain, significant medical or psychi-
atric conditions, chronic shoulder disease, severe obesity,
previous intra-articular injection of either knee or of any other
joint with steroids, previous intra-articular injection of the sig-
nal knee with hyaluronic acid, diagnostic arthroscopy, use of
systemic steroids or knee injury within 3 months of study entry,
history of surgery or surgical arthroscopy of the signal knee,
and recent therapy with a drug of the tetracycline class, with
calcitonin, systemic fluoride, bisphosphonate, glucosamine,
digoxin, warfarin, inhibitors, or inducers of cytochrome P450
3A4, 1,25 (OH)2 D3 or with more than 400 IU/day of vitamin
D2 or D3.
The study was conducted in 16 centers in the UK and 8 cent-
ers in Hungary between July 2002 and February 2004 in com-
pliance with International Conference on Harmonization
guidelines, the US Code of Federal Regulations, European
Community guidelines, and the Declaration of Helsinki. Each
study site's ethics committee approved the protocol, and all
patients provided written informed consent. An Independent
Data Monitoring Committee (IDMC) monitored unblinded data
for safety.
Treatments administered
Eligible patients were randomly assigned to receive orally
twice daily for 1 year onecapsule containing either placebo or
one of fourdoses of PG-116800 (25, 50, 100, or 200 mg).
The PG-116800 capsules were supplied by Procter & Gam-
ble Pharmaceuticals (Mason, OH, USA) as white opaque gel-Available online http://arthritis-research.com/content/9/5/R109
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atin shells containing PG-530742 (the dihydrated sodium salt
PG-116800), lactose monohydrate (National Formulary, NF),
and magnesium stearate NF. Placebo capsules were identical
in composition and appearance to the capsules containing
active drug but did not contain drug substance. During the in-
life portion of the study (November 2003), the IDMC recom-
mended discontinuing the 200-mg dose based on an
increased frequency of musculoskeletal adverse effects.
Outcome and safety assessments
The progression of joint space narrowing in the osteoarthritic
knee (structural primary endpoint) was evaluated by measur-
ing the 1-year change from baseline in minimum JSW in the
medial compartment of the tibiofemoral joint of the signal knee,
using microfocal knee radiographs obtained in the semiflexed
position. To ensure proper alignment of the tibial plateau and
centering of the tibial spines relative to the femoral notch, fluor-
oscopic positioning was performed before the radiograph was
acquired. Study radiographers in twocenters (one in Hungary
and one in the UK) performing microfocal x-ray underwent spe-
cific training and testing before participating in the study. The
reduction of symptoms and/or improvement of function of the
knee (symptomatic primary endpoint) was measured by the
Western Ontario and McMaster Universities osteoarthritis
index (WOMAC) total score (version3.1) at 1 year [29]. Sec-
ondary endpoints included the consumption of analgesics and
NSAIDs as pain medication for OA and the Patient Global
Assessment ('Considering all the ways your OA affects you,
how have you been in the last 48 hours?').
Tolerability and safety were evaluated at each visit through
interviews by the site personnel. All treatment-emergent
adverse events were recorded, and their severity (mild, moder-
ate, or severe) and relationship to the study drug (doubtful,
possible, or probable) were graded by the investigator. Clini-
cal laboratory tests, electrocardiograms, and chest radio-
graphs were performed regularly.
The occurrence of musculoskeletal effects was carefully mon-
itored because of musculoskeletal toxicity reported with other
MMP inhibitors in oncology trials [17]. Based on a literature
review, a working definition of the MMP inhibitor-associated
musculoskeletal syndrome (MSS) was developed and
included painless loss of range of motion (ROM) in large joints
(particularly in the shoulders), joint stiffness and joint swelling,
soft tissue pain, and fibrosis of palmar tendons (Dupuytren
contracture). To assess potential musculoskeletal toxicity,
each follow-up visit included serial measurements of shoulder
ROM (anterior flexion, abduction, internal rotation, and external
rotation) at the site by an appropriately trained person using a
goniometer; examination of palmar tendons for evidence of
palmar tendon fibrosis, tendinitis, fasciitis, or inflammation; and
elicitation of MSS symptoms through questioning. A diagnosis
of MSS was considered likely if a patient (a) developed palmar
fibrosis, (b) lost at least 30% of any shoulder ROM, as meas-
ured by goniometer, or (c) presented with musculoskeletal
signs or symptoms the investigator considered to be signifi-
cant and consistent with those previously reported in the liter-
ature. No specific blood biomarker of MMP inhibitor-related
musculoskeletal toxicity was identified and collected. Patients
with signs and symptoms consistent with MSS could undergo
ultrasound of the hands and shoulders at the investigators' dis-
cretion and the sponsor's recommendation. The IDMC
reviewed unblinded study data quarterly to enable the early
discontinuation of doses that appeared to be associated with
any unacceptable adverse events, with particular attention to
any evidence of MSS.
Sample size determination
The study was designed to detect a 50% reduction in JSW
change at 1 year with 80% power, using one-sided compari-
sons, each made at an α value of 0.10 (not adjusted). The
sample size of 75 patients per group (for a total of 375
enrolled) assumed a yearly loss in JSW of 0.2 mm, with a
standard deviation of 0.25 mm. Treatment groups were sized
to accommodate a 20% dropout rate. In addition, without
regard for multiple outcomes, the study had 80% power to
detect a 17% effect of treatment versus placebo with respect
to pain modification, as measured by the pain subscale of the
WOMAC index (assuming one-sided comparisons, each
made at an α value of 0.10, a placebo mean of 160 mm, and
a standard deviation of 70 mm).
Randomization method
Patients were randomly assigned to fivetreatment groups
using an Interactive Voice Response System (IVRS). Rand-
omization of patients was balanced according to their current
use of estrogens or selective estrogen-receptor modulators
(SERMs) in which twostrata were formed. An adaptative rand-
omization technique [30] was employed to better achieve
treatment balance within each site, each estrogen/SERM stra-
tum, and across the entire study. The pooled study center was
treated as a stratification factor for all applicable efficacy end-
point analyses. The treatment codes were controlled by the
clinical supplies department of Procter & Gamble
Pharmaceuticals.
Blinding
This was a double-blind study with limited access to the rand-
omization code. Study drug was dispensed according to the
instructions provided via the IVRS. The treatment each patient
received was not disclosed to study personnel, participants,
contractors (except for clinical supplies distributor and IVRS
contractors), or the sponsor (except for select clinical
supplies, pharmacovigilance, bioanalytical, and pharmacoki-
netics personnel).
Statistical analysis
An intent-to-treat (ITT) analysis was conducted on all patients
who were randomly assigned and took at least one dose ofArthritis Research & Therapy    Vol 9 No 5    Krzeski et al.
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study drug. Any missing data for these patients were not
imputed in the primary analyses. Thus, the efficacy analyses
were based on the ITT patients with observed data at the time
point under consideration. Paired t tests were used to test
change from baseline values.
The 1-year change from baseline in minimum JSW in the
medial compartment of the tibiofemoral joint of the signal knee
was determined from the 12-month radiograph back to base-
line. The significance of the 1-year change from baseline in
minimum JSW and WOMAC total score was estimated using
an analysis of variance. Minimum JSW change estimates were
adjusted for baseline JSW, pooled center, and baseline use of
estrogen or SERM drug replacement therapy as covariates.
WOMAC change estimates were adjusted for baseline total
scores, pooled center, and baseline use of estrogen or SERM
drug replacement therapy as covariates. Each dose group was
compared with the placebo control group. Each of these com-
parisons was made using a one-sided test with an α value of
0.10. Secondary endpoints were analyzed in a similar fashion.
Safety analyses included the ITT population. ROM measure-
ments were analyzed and adjusted for pooled study centers as
covariates. Comparisons between treatment groups were
made to placebo for each visit. Additionally, the proportion of
patients with detectable decreases in ROM was summarized.
The proportion of patients with palmar tendon fibrosis, palmar
tendon tendonitis, or palmar tendon fasciitis was summarized.
Adverse events were tabulated and summarized according to
the Medical Dictionary for Regulatory Activities (MedDRA).
Percentages of patients reporting a decrease in shoulder
ROM were compared to placebo by means of the Fisher exact
test. Changes in joint symptom severity were tabulated and
summarized, and percentages of patients reporting an
increase in joint symptoms were compared to placebo by
means of the Cochran-Mantel-Haenszel test after adjusting for
pooled centers. P values for safety analyses were provided as
flags for further investigation and were not adjusted for multi-
ple testing.
Results
A summary of patient accountability is presented in Table 1. Of
401 patients randomly assigned into the study, 395 took at
least one dose of study drug (ITT population). The per-protocol
population comprised 296 patients. Twenty-one patients in
the 200-mg dose group were withdrawn from the study for
safety reasons per IDMC recommendation, which was classi-
fied as a major protocol deviation. All patients were analyzed
according to group assignment. Overall, treatment groups
were balanced with regard to demographics and baseline
characteristics (Table 2). The majority of patients were post-
menopausal females who were not using hormone replace-
ment therapy.
Efficacy results
Overall, PG-116800 administration did not result in slower
progression of joint space narrowing compared with that
observed with placebo. There was no statistically significant
difference between placebo and any of the PG-116800
groups in mean change in minimum JSW of the signal knee
Table 1
Patient accountability
Placebo 25 mg 50 mg 100 mg 200 mg Overall
n(%) n (%) n (%) n (%) n (%) n(%)
Patients randomly assigned 80 81 80 80 80 401
Patients who took at least onedose of study drug 77 80 79 80 79 395
Patients in per-protocol populationa 66 67 64 64 35 296
Patients completing 12 months of dosing 69 (90%) 65 (81%) 66 (84%) 64 (80%) 19 (24%) 283 (72%)
Patients who withdrew 8 (10%) 15 (19%) 13 (16%) 16 (20%) 60 (76%) 112 (28%)
Reason for withdrawal
Adverse event 4 (5%) 10 (13%) 6 (8%) 11 (14%) 34 (43%) 65 (16%)
Protocol violation 1 (1%) 1 (1%) 2 (3%) 2 (3%) 1 (1%) 7 (2%)
Voluntary withdrawal 3 (4%) 3 (4%) 4 (5%) 2 (3%) 3 (4%) 15 (4%)
Lost to follow-up 0 (0%) 1 (1%) 0 (0%) 1 (1%) 0 (0%) 2 (<1%)
Unable to meet protocol criteria 0 (0%) 0 (0%) 1 (1%) 0 (0%) 1 (1%) 2 (<1%)
IDMC recommendation 0 (0%) 0 (0%) 0 (0%) 0 (0%) 21 (27%) 21 (5%)
n (%) = number and percentage of patients. % = n/N × 100.
aPer-protocol population refers to patients who completed the study as per protocol, including 75% compliance with randomized study drug 
during the course of the trial.
IDMC, Independent Data Monitoring Committee.Available online http://arthritis-research.com/content/9/5/R109
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after 1 year of treatment (Table 3). The decrease from baseline
in mean JSW of the signal knee was observed in all dose
groups at month 12 and was statistically significant in all with
the exception of the 25-mg group. Similarly, analysis of the
symptomatic primary endpoint did not demonstrate statisti-
cally significant differences between placebo and each of the
PG-116800 groups on total WOMAC scores (Table 4). Anal-
ysis of secondary endpoints showed that Patient Global
Assessment scores improved significantly from baseline over
the course of 12 months in all groups with the exception of the
200-mg group, but there were no differences between treat-
ment groups (data not shown). At month 12, the consumption
of pain medication for OA had decreased from baseline in all
groups, the change from baseline reaching statistical signifi-
cance in the placebo group only (data not shown).
Safety results
The proportion of patients reporting adverse events was great-
est in the twohighest dose groups (Table 5). Serious adverse
events and withdrawals due to adverse events occurred with
the highest frequency in the 200-mg group, in which adverse
events were the primary cause of withdrawal. The majority of
adverse events, serious adverse events, and withdrawals due
to adverse events were musculoskeletal and connective tissue
disorders. Arthralgia was the single most frequent adverse
event overall (35% of all patients) and was also the most fre-
quent serious adverse event and reason for withdrawal. Two
patients, one in the 100-mg group and one in the 200-mg
group, died of pulmonary embolism and cardiac failure,
respectively, during the study. The investigators considered
their deaths to be unrelated to study drug.
Objective monitoring of musculoskeletal toxicity included goni-
ometer assessment of shoulder ROM at each visit. Of the 391
patients who had at least onevalid shoulder ROM measure-
ment during a follow-up visit, 90 (23%) had a decrease of at
least 30% from baseline for at least one ROM measurement of
either shoulder (Table 6). The percentage of patients with
changes in ROM was statistically significantly greater in the
twohighest dose groups relative to placebo. Twenty-nine
Table 2
Demographic and baseline characteristics (intent-to-treat population)
Parameter Placebo 25 mg 50 mg 100 mg 200 mg
(n = 77) (n = 80) (n = 79) (n = 80) (n = 79)
Age in years, mean (standard error of the mean) 62.0 (0.92) 62.4 (0.86) 62.6 (0.92) 62.9 (0.95) 63.1 (0.80)
Males, number (percentage) 23 (30%) 20 (25%) 18 (23%) 23 (29%) 30 (38%)
Females, number (percentage) 54 (70%) 60 (75%) 61 (77%) 57 (71%) 49 (62%)
Estrogen/SERM use among females, number (percentage)
Yes 5 (9%) 9 (15%) 6 (10%) 5 (9%) 4 (8%)
No 49 (91%) 51 (85%) 55 (90%) 52 (91%) 45 (92%)
SERM, selective estrogen receptor modulator.
Table 3
One-year change from baseline in joint space width of the signal knee (intent-to-treat population)
Treatment group Numbera Joint space width 
at baseline
Joint space width 
at month 12
One-year change 
from baseline
Mean 1-year 
percentage 
change from 
baseline
P valueb (90% CI)
Mean (SEM) Mean (SEM) Least square 
mean (SEM)
Placebo 71 3.386 (0.085) 3.252 (0.096) -0.136c (0.063) -4.00
25 mg 66 3.350 (0.094) 3.307 (0.105) -0.044 (0.062) -1.24 0.127 (-0.012, ∞)
50 mg 67 3.346 (0.094) 3.123 (0.113) -0.226c (0.065) -7.07 0.869 (-0.193, ∞)
100 mg 69 3.413 (0.094) 3.218 (0.129) -0.200c (0.065) -7.61 0.789 (-0.166, ∞)
200 mg 52 3.466 (0.108) 3.278 (0.138) -0.192c (0.072) -6.72 0.740 (-0.166, ∞)
aNumber of patients with available data at baseline and month 12. bOne-sided P value: The mean change from baseline in each treatment group 
was compared to placebo by means of an analysis of variance after adjusting for pooled centers, baseline use of estrogen replacement therapy or 
selective estrogen receptor modulator drugs, and baseline joint space width. cThe mean change from baseline was significantly different from zero 
using a paired t test within each treatment group.
CI, confidence interval for mean difference; SEM, standard error of the mean.Arthritis Research & Therapy    Vol 9 No 5    Krzeski et al.
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patients (7%) had an ROM decrease of at least 30% in both
shoulders. Reproducibility of the decrease in shoulder ROM
(that is, decrease of 30% in a measurement at twoconsecutive
visits) was used as a practical measure of specificity of the
finding. Of 376 patients with valid measurements, 40 patients
(11%) had a decrease of at least 30% in the same measure-
ment for either shoulder at twoor more consecutive visits. The
decrease mostly affected shoulder internal and external rota-
tions; fewer patients had decreases in shoulder abduction and
anterior flexion. Finally, 34 of 391 patients (9%) had decreases
of at least 30% in two or more ROM measurements of either
shoulder at the same visit. The percentage of patients with two
or more ROM decreases in the twohighest dose groups was
statistically significantly greater relative to placebo (Table 6).
Adverse events affecting the hand were reported in 52 of 395
patients (13%), nearly half of whom were in the 200-mg group
(Table 7). Common signs included hand oedema (5 patients),
palmar fibrosis (15 patients), Dupuytren contracture (5
patients), and tendon thickening/nodules (3 patients). Most
patients with hand involvement (16 patients) had asympto-
matic nodules without function loss (contracture), hand pain,
or hand oedema. Of the 7 symptomatic patients, 4 were in the
200-mg group, 2 in the 100-mg group, and 1 in the 50-mg
group. A mild function loss in hands (mild contracture) was
reported in 5 symptomatic patients, 2 of whom had accompa-
nying pain and localized oedema, which were not reported as
separate adverse events. Two other symptomatic patients
included 1 patient with mild hand pain (localized hypersensitiv-
Table 4
One-year change from baseline in total WOMAC scores (intent-to-treat population)
Treatment group Numbera WOMAC total score 
at baseline
WOMAC total score 
at month 12
One-year change 
from baseline
P valueb (90% CI)
Mean (SEM) Mean (SEM) Least square mean 
(SEM)
Placebo 67 41.8 (2.16) 32.9 (2.78) -9.1c (2.81)
25 mg 61 42.6 (2.90) 35.9 (3.21) -6.7c (2.78) 0.746 (-∞, 7.0)
50 mg 62 49.1 (2.46) 37.1 (3.20) -10.0c (2.88) 0.403 (-∞, 3.7)
100 mg 62 50.9 (2.66) 42.4 (3.10) -5.8c (2.92) 0.823 (-∞, 8.0)
200 mg 30 47.2 (3.70) 36.5 (4.54) -9.3c (3.96) 0.483 (-∞, 5.6)
25 mg versus placebo 0.485d
50 mg versus placebo 0.631d
100 mg versus 
placebo
0.374d
200 mg versus 
placebo
0.610d
aNumber of patients with available data at baseline and month 12. bOne-sided P value: The mean change from baseline in each treatment group 
was compared to placebo by means of an analysis of variance after adjusting for pooled centers, baseline use of estrogen replacement therapy or 
selective estrogen receptor modulator drugs, and baseline total scores. cThe mean change from baseline was significantly different from zero 
using a paired t test within each treatment group. dOne-sided P value was based on between-group comparison of mean change from baseline by 
means of repeated-measures analysis adjusted for pooled centers, baseline total scores, and baseline use of estrogen replacement therapy or 
selective estrogen receptor modulator drugs.
CI, confidence interval for mean difference; SEM, standard error of the mean; WOMAC, Western Ontario and McMaster Universities osteoarthritis 
index.
Table 5
Summary of adverse events (intent-to-treat population)
Placebo 25 mg 50 mg 100 mg 200 mg
(n = 77) (n = 80) (n = 79) (n = 80) (n = 79)
Patients with adverse events, number (percentage) 52 (68%) 51 (64%) 51 (65%) 62 (78%) 62 (78%)
Patients who withdrew, number (percentage) 8 (10%) 15 (19%) 13 (16%) 16 (20%) 60a (76%)
Patients with serious adverse events, number (percentage) 8 (10%) 7 (9%) 12 (15%) 10 (13%) 17 (22%)
Patients who died, number (percentage) 0 (0%) 0 (0%) 0 (0%) 1 (1%) 1 (1%)
aIncludes 21 patients withdrawn per Independent Data Monitoring Committee recommendation.Available online http://arthritis-research.com/content/9/5/R109
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ity) and another patient with pain and oedema in the hand with-
out any functional loss. The first cases of palmar fibrosis
appeared at month3, and the number of affected patients in
the 200-mg dose group reached statistical significance versus
placebo at month9 (18% versus 1%; p = 0.001). The finding
of fibrosis on hand palpation was confirmed by hand
ultrasound in 20 patients. Ultrasound was not a scheduled
procedure in the study protocol. The usual appearance of
fibrosis on ultrasound consisted of elongated or oblique bands
along flexor tendons, in their proximity but not within the ten-
dons. Their size varied depending on the examination tech-
nique (palpation versus ultrasound) and ranged from a few
millimeters to approximately 2 cm in length. In one case, a
thickening of fascia palmaris of 6 cm in length was described.
The threemost frequent shoulder adverse events were arthral-
gia, stiffness, and myalgia. The first cases of shoulder arthral-
gia, which affected either shoulder with similar frequency,
appeared after 1 month of dosing. Over the course of the
whole study, 13%, 16%, 13%, 21%, and 25% of patients,
respectively, in the placebo, 25-mg, 50-mg, 100-mg, and 200-
mg dose groups reported shoulder arthralgia. Shoulder stiff-
ness, which was usually isolated but sometimes accompanied
by stiffness in other joints, was reported starting at month6.
Over the course of the study, 1%, 4%, 6%, 9%, and 6% of
patients, respectively, in the placebo, 25-mg, 50-mg, 100-mg,
and 200-mg groups reported shoulder stiffness. Shoulder
myalgia generally affected the deltoid muscle and was
reported in 1%, 1%, 4%, 3%, and 6% of patients, respectively,
in the placebo, 25-mg, 50-mg, 100-mg, and 200-mg groups
over the course of the study. The threemost frequently
reported shoulder adverse events could represent different
reporting of a similar symptomatology. An analysis combining
the threemost frequent shoulder adverse events showed a
dose-related response starting after 3 months of dosing, con-
tinuing through months6 and 9, and disappearing at month 12
(data not shown).
Other symptoms included neck pain (3%, 4%, 4%, 6%, and
10% of patients, respectively, in the placebo, 25-mg, 50-mg,
Table 6
Changes from baseline in shoulder range of motion (intent-to-treat population)
Placebo 25 mg 50 mg 100 mg 200 mg
Patients with ≥30% decrease from baseline in ≥1 ROM 
measurement at any postbaseline visit for either shoulder, number 
(percentage)
12/77 (16%) 11/79 (14%) 18/78 (23%) 24/79 (30%) 25/78 (32%)
P valuea 0.824 0.310 0.036 0.023
Patients with ≥30% decrease from baseline in the same ROM 
measurement at 2 or more consecutive postbaseline visits for 
either shoulder, number (percentage)
4/74 (5%) 5/78 (6%) 8/74 (11%) 12/77 (16%) 11/73 (15%)
P valuea 1.000 0.367 0.062 0.061
Patients with ≥30% decrease from baseline in 2 or more ROM 
measurements at the same postbaseline visit for either shoulder, 
number (percentage)
2/77 (3%) 2/79 (3%) 5/78 (6%) 13/79 (16%) 12/78 (15%)
P valuea 1.000 0.442 0.005 0.009
aTreatment groups were compared to placebo by means of the Fisher exact test. ROM, range of motion.
Table 7
Patients with hand adverse events (intent-to-treat population)
Placebo 25 mg 50 mg 100 mg 200 mg
Patients with hand adverse events, number (percentage) 5/77 (6%) 8/80 (10%) 9/79 (11%) 7/80 (9%) 23/79 (29%)
Patients with particular hand findings (hand oedema overlapped with other 
findings), number
H a n d  o e d e m a 00 11 3
Palmar fibrosis 0 1 1 2 12
Dupuytren contracture 0 1 0 3 1
Tendon thickness/nodules 0 0 0 0 2
Symptomatic patients, number 0 0 1 2 4Arthritis Research & Therapy    Vol 9 No 5    Krzeski et al.
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100-mg, and 200-mg groups), which could be due to referred
pain originating in the shoulder, and shoulder periarthritis (1%,
3%, 1%, 4%, and 6% of patients, respectively, in the placebo,
25-mg, 50-mg, 100-mg, and 200-mg groups). Shoulder ultra-
sounds were performed at the investigator's discretion in
some symptomatic patients. Of 13 symptomatic patients in
whom rotator cuff rupture (partial or complete tear) was found
on shoulder ultrasound during the study, 3 patients each were
in the placebo, 50-mg, 100-mg, and 200-mg groups and 1
patient was in the 25-mg group. Few patients (7%) had a com-
bination of shoulder and hand symptoms that appeared inde-
pendent of each other.
Most patients withdrawn from the study because of develop-
ment of musculoskeletal adverse events were followed until
resolution or stabilization of symptoms. Cessation of MMP
inhibitor administration seemed to bring symptomatic relief as
well as improvement in ROM in patients with shoulder involve-
ment. Among 19 patients followed up for clinically significant
shoulder involvement, the improvement was complete in 10
patients after a mean period of 122 days and partial in 3
patients after a mean period of 107 days (partial means that
the symptoms or signs decreased but never returned to base-
line status) (Table 8). Additionally, 3 patients with shoulder
involvement recovered completely while still exposed to active
drug and 3 other patients recovered partially. Complete recov-
ery was seemingly promoted by local glucocorticoid injections
in 4 patients and physiotherapy in 5 patients. Partial recovery
was promoted by local glucocorticoid injections in 1 patient
and physiotherapy in another patient. Patients were also
administered NSAIDs and paracetamol for the shoulder symp-
toms or index knee OA. Recovery from shoulder symptoms
was faster in patients who were exposed to the MMP inhibitors
for a shorter period of time. Six patients with shoulder involve-
ment underwent temporary drug interruption followed by drug
rechallenge. The symptoms recurred in 4 of these patients. Of
the 21 patients followed for hand adverse events, only 2
recovered completely after a mean period of 224 days from
their last dose of study drug. Eleven patients recovered
partially after a mean period of 210 days and the hand fibrosis
was unchanged in 7 patients after a mean period of 196 days
after stopping the study drug (partial recovery means that
either the symptoms decreased or the extent of fibrosis
decreased in size in clinical or ultrasound assessment) (Table
8). Of the 3 patients followed for involvement of both
shoulders and hands, 2 patients recovered partially after a
mean period of 170 days from the last dose of study drug (par-
tial recovery means that symptoms or signs in at least one site
of involvement, usually the shoulder, decreased). Additionally,
1 patient with both shoulder and hand involvement recovered
partially while still taking active drug. Initial symptoms of hand
pain or oedema, which accompanied the diagnosis of hand
fibrosis, tended to disappear after stopping study drug.
Table 8
Follow-up data after PG-116800 withdrawal in patients with clinically significant shoulder findings and hand adverse events
Level of 
recovery
Number of 
patients
Mean time 
(days)
Median time 
(days)
Minimum time 
(days)
Maximum time 
(days)
Comments
Shoulder Complete 10 122 81 5 316 Additional 3 
patients 
recovered while 
still on drug
Partial 3 107 138 30 154 Additional 3 
patients 
recovered while 
still on drug
Unchanged vs. 
baseline
0
Hand Complete 2 224 224 163 285
Partial 12 210 213 93 329
Unchanged vs. 
baseline
7 196 184 77 303
Both Complete 0
Partial 2 170 170 79 261 Additional 1 
patient 
recovered while 
still on drug
Unchanged vs. 
baseline
0Available online http://arthritis-research.com/content/9/5/R109
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Discussion
This proof-of-concept and dose-ranging study failed to dem-
onstrate efficacy of PG-116800, an MMP inhibitor, in modify-
ing the course of knee OA in patients with mild to moderate
disease during a 12-month treatment period, as determined by
microfocal x-ray assessment of JSW and analysis of WOMAC
total scores, despite promising results of nonclinical studies
[9,10,12].
The study confirmed that microfocal radiography is a sensitive
tool in detecting a decrease in JSW in osteoarthritic patients
over the course of a 12-month period. The progression of OA
as evidenced by a decreasing JSW coexisted with sympto-
matic improvement from baseline in all treatment groups,
including placebo. Significant symptomatic placebo response
has been observed in OA studies of both intra-articular and
oral medications and was noted in other recent studies [31-
34]. This study seems to confirm that patients are likely to
improve symptomatically and that the placebo effect persists
for at least 12 months. Progression of JSW narrowing accom-
panied by symptomatic improvement over the course of a 1-
year time period calls for further research in surrogate markers
of OA activity and progression.
Although the majority of the cases described in the literature
have been associated with the use of marimastat in patients
with cancer, musculoskeletal toxicity has been reported in
association with most, if not all, other MMP inhibitors. Muscu-
loskeletal effects have been observed in preclinical studies
with other MMP inhibitors [35]. In preclinical studies con-
ducted with PG-116800, swelling was observed around the
joints of both rats and dogs during chronic toxicology studies
(3 and 6 months in rats and 12 months in dogs;, Procter &
Gamble Pharmaceuticals, unpublished data). In apparent rela-
tion to the swelling, rats and dogs had accumulation of colla-
gen associated with the joint structures. In dogs, after 12
months of study, proliferation of periosteal fibrous tissue and
resorption of bone were observed in the joint. The effects
appeared to be reversible when observed at the end of a 3-
month recovery period.
Because the potential musculoskeletal toxicity of MMP inhibi-
tors was recognized before the study start, safety measures
included shoulder ROM assessment and monitoring with an
IDMC. Although a detailed hand examination was part of the
baseline physical examination, investigators were sensitized to
hand findings after cases of asymptomatic nodules were
observed. IDMC-driven withdrawal of patients in the 200-mg
dose group could result in cases of musculoskeletal toxicity
being over-reported at withdrawal in this group following the
unblinding. The hand findings had a striking clinical resem-
blance to those of early development of Dupuytren
contracture.
One of the major challenges in identifying patients with drug-
related musculoskeletal toxicity in the study population was
the need to differentiate from the symptoms and signs of OA
itself. Although upper girdle involvement in OA is less frequent
than involvement of hips and knees, it is not uncommon for the
two to coexist in the same patient. Additionally, in published
series, up to 50% of asymptomatic patients more than 60
years of age had partial or full rotator cuff tears in shoulder
imaging studies [36]. Since shoulder ultrasound was not part
of the screening process in this study but was used for further
workup in some patients reporting shoulder symptoms, the
finding of a rotator cuff tear was not helpful in differentiating
drug toxicity from age-related tissue degeneration.
The occurrence of the most frequently reported shoulder
adverse events (arthralgia, myalgia, and joint stiffness) fol-
lowed a time- and dose-response pattern. This pattern disap-
peared after 12 months. Early termination of the study by
patients in the highest dose group as per the IDMC recom-
mendation after most of the patients had been dosed for 6
months offers a plausible explanation together with early with-
drawals of symptomatic patients.
A number of theories to explain the occurrence of the muscu-
loskeletal effects observed with MMP inhibitors have been
offered, but none of them has definitive proof to support it. Inhi-
bition of sheddase activity attributed to hydroxamate-based
MMP inhibitors might be responsible for musculoskeletal
symptoms [4]. Sheddase activity converts membrane-bound
cytokines and receptors to inactive forms. Therefore, inhibiting
this conversion could result in inflammation. In support of this
theory, patients treated with BMS-275291 (which has
reduced activity against sheddases) initially did not experience
MSS [4]. This finding was verified after longer treatment dura-
tion when similar adverse events were reported. Another the-
ory was that musculoskeletal toxicity might be caused by
MMP-1 inhibition [4]. In an attempt to minimize these effects,
Bayer Corp. (West Haven, CT, USA) and Agouron
Pharmaceuticals Inc. (La Jolla, CA, USA) developed tanomas-
tat and prinomastat, which strongly inhibit MMP-2 and -9 and
weakly inhibit MMP-1, -7, and -11. However, prinomastat con-
tinued to exhibit musculoskeletal toxicity, whereas tanomastat
was abandoned for lack of efficacy in oncology indications
[4,37].
Conclusion
The study did not demonstrate efficacy of PG-116800, an
MMP inhibitor, in the treatment of patients with knee OA. It
indicated that musculoskeletal side effects compromise the
safety of long-term (greater than 3 months) systemic adminis-
tration of the compound. Shoulders were affected clinically,
with a decrease in ROM and an increase in pain largely revers-
ible upon drug discontinuation. A dose- and time-related focal
accumulation of tissue consistent with palmar tendon fibrosis
was observed after 2 to 3 months of treatment. These muscu-Arthritis Research & Therapy    Vol 9 No 5    Krzeski et al.
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loskeletal side effects were similar to those reported for other
MMP inhibitors. This is likely to reflect a class effect, as these
adverse effects are now reported for most of the MMP inhibi-
tors, and this further suggests that these agents are unlikely to
be of practical clinical use for the treatment of OA.
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